Business Context and Reporting Period
This Form 8-K Current Report was filed by CorMedix Inc. on April 23, 2020, covering events occurring on April 17, 2020. The filing discloses the execution of a new employment agreement with John L. Armstrong, Jr., the Company's Executive Vice President, Technical Operations.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation terms.
- Base Salary: $325,000 annually.
- Annual Bonus: Eligible for up to 35% of base salary, contingent on company objectives.
- Equity Grants: Annual grants of restricted stock, RSUs, or stock options at the Board's discretion.
Material Changes
The primary material change is the replacement of Mr. Armstrong's prior employment agreement (dated March 2017) with a new three-year agreement effective April 17, 2020. The new agreement includes automatic one-year renewals unless terminated with 90 days' notice.
Outlook, Risks, and Unusual Items
Termination Provisions:
- For Cause: Immediate forfeiture of all unvested equity and options; payment limited to accrued compensation.
- Without Cause/Good Reason: Entitles Mr. Armstrong to 9 months of base salary, prorated bonus, COBRA premium payments, and acceleration of certain equity vesting.
- Corporate Transaction: Triggers full vesting of all equity awards and options.
Restrictive Covenants: A non-compete provision prohibits Mr. Armstrong from engaging in businesses involving preventive anti-infective products (specifically Neutrolin or taurolidine) for 12 months following separation.
Investor Verification Checklist
- Verify the total potential cash compensation (salary + maximum bonus) against the Company's current cash position.
- Review the specific definitions of "Cause" and "Good Reason" in the full agreement (Exhibit 10.1) to assess termination risk.
- Confirm the impact of the 12-month non-compete clause on the Company's ability to hire or retain technical talent in the anti-infective sector.
- Check subsequent filings for any changes to the Company's liquidity that might affect the ability to fund the 9-month severance package if triggered.